Indications
Iron Sucrose is used to treat Iron Sucrose deficiency in these situations: where there is a clinical need for a rapid Iron Sucrose supply, in patients who can not tolerate oral Iron Sucrose therapy or who are non-compliant, and in active inflammatory bowel disease where oral Iron Sucrose preparations are ineffective. It is also used in non-dialysis dependent-chronic kidney disease (NDD-CKD) patients receiving an erythropoietin, and in NDD-CKD patients not receiving an erythropoietin. The same applies to hemodialysis dependent-chronic kidney disease (HDD-CKD) patients receiving an erythropoietin, and to peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients receiving an erythropoietin. Iron Sucrose is also indicated for Iron Sucrose deficiency anaemia in patients undergoing surgical procedures, patients donating blood and postpartum patients.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
The therapeutic class of Iron Sucrose is haematinic. Iron Sucrose Injection USP is a brown, sterile, aqueous complex of Polynuclear Iron (III) Hydroxide in Sucrose, made for intravenous use. The product contains approximately 30% Sucrose w/v (300 mg/ml) and has a pH of 10.5 to 11.1.
After intravenous administration, the reticuloendothelial system dissociates Iron Sucrose Injection into Iron and Sucrose, and the Iron moves from the blood to a pool of Iron in the liver and bone marrow. Ferritin, an Iron storage protein, binds and sequesters Iron in a nontoxic form, and from there the Iron is easily available. Iron binds to plasma transferrin, which carries it within the plasma and the extracellular fluid to supply the tissues. The transferrin receptor sits in the cell, and the transferrin-receptor complex is returned to the cell membrane. Transferrin without Iron (apotransferrin) is then released to the plasma. Inside the cell, the Iron becomes (mostly) haemoglobin in circulating red blood cells (RBCs). In Iron deficiency, transferrin synthesis increases and ferritin production falls. The converse is true when Iron is plentiful.
Its elimination half-life is 6 h, total clearance is 1.2 L/h, non-steady state apparent volume of distribution is 10.0 L and steady state apparent volume of distribution is 7.9 L. The Iron component of Iron Sucrose appears to distribute mainly in blood and to some extent in extravascular fluid. A significant amount of the administered Iron distributes in the liver, spleen and bone marrow, and the bone marrow is an Iron trapping compartment and not a reversible volume distribution. The sucrose component is eliminated mainly through urinary excretion.
Pregnancy & Breastfeeding
Iron Sucrose is listed as Pregnancy Category-B. There are no adequate and well controlled studies in pregnant women, so it should be used during pregnancy only if clearly needed.
It isn't known whether Iron Sucrose passes into human milk. Many drugs do pass into milk, so caution should be exercised when it is given to a nursing woman.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.